不同剂量丙种球蛋白治疗川崎病的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical efficacy of different dose of gammag lobulin in children with Kawasaki disease(KD).Methods Forty children with KD from February 2014 to December 2015 were selected and randomly divided into the control group and the observation group,with 20 cases in each group.The control group was treated with lowdose gamma globulin,while the observation group was treated with high dose gammag lobulin.The time of fever clearance and hospitalization,the incidence of coronary artery lesions,and the levels of C-reactionprotein(CRP)and procalcitonin(PCT)before and after treatment of children in two groups were compared.Results The time of fever clearance and hospitalization of children in the observation group[(21.37±2.85)h,(3.24±0.89)d]were shorter than those in the control group[(33.09±3.17)h,(4.98±1.15)d],the differences were statistically significant(P＜0.05);the incidence of coronary artery lesions after 1 year follow-up in the observation group(5.00%)was lower than that in the control group(30.00%),the difference was statistically significant(P＜0.05).After treatment,the levels of CPR and PCT of children in two groups were decreased,comnpared with those before treatment,and those in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion The application of high dose of gamma globulin has significant effect in children with KD,which can shorten the time of fever clearance and hospitalization,reduce coronary artery lesions and decrease the levels of CRP and PCT of children.It is worthy of clinical application.

Key words： Gamma globulin Kawasaki disease Dose Procalcitonin C-reactive protein

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Wang-bin
	OU Qiu-yan
	LIN Dong-li

Cite this article:

HUANG Wang-bin,OU Qiu-yan,LIN Dong-li. Clinical efficacy of different dose of gamma globulin in children with Kawasaki Disease[J]. 中国当代医药, 2017, 24(8): 99-101.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I8/99

[1]	Pavone P，Cocuzza S，Passaniti E，et al.Otorrhea in Kawasaki disease diagnosis complicated by an EBV infection：coincidental disease or a true association[J].Eur Rew Med Pharmacol Sci，2013，17（7）：989-993.
[2]	王雪芳，刘纯义，刘文娟.不同剂量丙种球蛋白对川崎病患儿的疗效及对冠状动脉病变的影响[J].当代医学，2013，9（16）：81-82.
[3]	Ghelani SJ，Sable C，Wiedermann，BL，et al.Increased incidence of incomplete kawasaki disease at a pediatric hospital after publication of the 2004 american heart association guidelines[J].Pediat Cardiol，2012，33（7）：1097-1103.
[4]	逯艳梅，曹甦，丁春杰.川崎病患儿急性期血清降钙素原、C-反应蛋白的变化及临床意义[J].右江医学，2015，43（5）：583-585.
[5]	Yu Y，Sun K，Xue H，et al.Usefulness of real-time 3-dimensional echocardiography to identify and quantify left ventricular dyssynchrony in patients with kawasaki disease[J].J Ultrasound Med，2013，32（6）：1013-1021.
[6]	李鹏，周忠蜀.川崎病患儿血清降钙素原的变化及其意义[J].山西医科大学学报，2015，46（2）：179-180.
[7]	孟祥春，马伟科，胡宇慧，等.川崎病患儿血清PCT变化及其与冠状动脉损害的关系研究[J].医学研究杂志，2013，42（1）：169-171.
[8]	晏萍兰，李萍.静脉注射丙种球蛋白治疗小儿川崎病不良反应观察与护理[J].实用医学杂志，2012，28（8）：1366-1368.
[9]	闫辉，万宏，杜军保，等.静脉注射丙种球蛋白无反应型川崎病的危险因素及预测分析[J].实用儿科临床杂志，2012，27（21）：1637-1640.
[10]	张敏，胡秀芬.丙种球蛋白无反应型川崎病研究进展[J].中华实用儿科临床杂志，2013，28（21）：1672-1676.
[11]	李丰，张园海，仇慧仙，等.静脉注射丙种球蛋白无反应型川崎病的研究进展[J].临床儿科杂志，2013，31（3）：283-286.
[12]	蒋勇，赵梦，李维禧，等.初始剂量静脉用丙种球蛋白治疗无反应川崎病的临床特征和预测指标[J].中华实用儿科临床杂志，2015，30（9）：676-680.
[13]	王航政.丙种球蛋白与阿司匹林联合丹参注射液治疗川崎病临床研究[J].国际中医中药杂志，2016，38（12）：1083-1086.
[14]	郭志芬.大剂量静脉滴注丙种球蛋白防止川崎病患儿冠伏动脉损害的效果评价及护理[J].中国实用护理杂志，2012，28（19）：45-47.
[15]	刘凡，丁艳，尹薇，等.对静脉注射丙种球蛋白无反应型川崎病临床分析[J].实用儿科临床杂志，2012，27（21）：1670-1671.